



ImpediMed Limited
Suite 31C, 12-18 Tryon Rd
Lindfield NSW 2070
Australia

E: investorrelations@impedimed.com
W : impedimed.com

27 August 2026

Companies Announcements Office
Australian Securities Exchange

Appendix 4E – Financial year ended 30 June 2026

ImpediMed Limited (ASX:IPD) provides the attached Appendix 4E – Preliminary Final Report for the financial year ended 30 June 2026.

Approved for release by the Board of ImpediMed Limited.

For more information, contact Leanne Ralph, Company Secretary, at
leanne.ralph@bellev.com.au

Appendix 4E
ImpediMed Limited ABN 65 089 705 144
Preliminary Final Report

- 1 Reporting period:** **Year ended 30 June 2026**
Prior Corresponding Reporting Period: Year ended 30 June 2025

2 Results for announcement to the market

		% change		\$000
Revenue	up	15%	to	14,613
(Loss) from ordinary activities after tax attributable to members	up	7%	to	-24,907
(Loss) for the period attributable to members	up	7%	to	-24,907
Dividends				
There were no dividends declared and paid during the reporting period on ordinary shares.				
There were no dividends proposed and not yet recognised as a liability during the reporting period.				
Dividend Record Date	Not applicable			
Net tangible assets per security		30 June 2026		30 June 2025
Net tangible assets per security		0.00 cents		0.37 cents

Additional Appendix 4E disclosure requirements are included in the 30 June 2026 Annual Financial Statements lodged with this document. The report is based on the 30 June 2026 Annual Financial Statements which are audited by Ernst & Young and are not subject to dispute, modification, or qualification. The information contained in this document should be read in conjunction with the ImpediMed Limited Annual Financial Report for the year ended 30 June 2026 and any public announcements made by ImpediMed Limited and its controlled entities during the year.